First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies - Irenaeus - 2019 - International Journal of Cancer - Wiley Online Library
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies | Cellular & Molecular Immunology
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo- controlled, proof-of-concept study - The Lancet Rheumatology
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement - ScienceDirect
Anti-CD40 agonistic antibody eradicates tumor and induces transient... | Download Scientific Diagram
Frontiers | CD40L and Its Receptors in Atherothrombosis—An Update
The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy - Parker Institute for Cancer Immunotherapy
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma | Nature Communications
CD40: Targeting Co-Stimulatory Pathways for Cancer Immunotherapy
CDX-1140, A Novel Agonist CD40 Antibody with Potent Anti-lymphoma Activity
With the High Potential in Cancer Immunotherapy, CD40 Is Triggering Attention - Cusabio
Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients | Arthritis Research & Therapy | Full Text
List of clinically used agonistic CD40 antibodies | Download Scientific Diagram
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study - The Lancet Oncology
Side effects of CD40 agonistic antibodies versus fusion molecules. | Download Scientific Diagram
Cells | Free Full-Text | Targeting the CD40-CD154 Signaling Pathway for Treatment of Autoimmune Arthritis
Anti-CD40 agonist antibodies may be the way to go for bladder cancer
Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment - Van Audenaerde - 2020 - Clinical & Translational Immunology - Wiley Online Library
CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma - Journal of Hepatology
Frontiers | Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients | Arthritis Research & Therapy | Full Text
Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis | Neurology Neuroimmunology & Neuroinflammation
IJMS | Free Full-Text | FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies
